Test

The chart shows the growth of an initial investment of $10,000 in Test, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Jun 29, 2021, Test's average daily return is +0.02%, while the average monthly return is +0.40%. At this rate, an investment would double in approximately 14.5 years.

Historically, 62% of months were positive and 38% were negative. The best month was Nov 2022 with a return of +4.4%, while the worst month was Sep 2022 at -4.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 2 months.

On a daily basis, Test closed higher 56% of trading days. The best single day was Nov 10, 2022 with a return of +1.8%, while the worst single day was Apr 4, 2025 at -2.2%.

Test has an annualized alpha of 2.74%, beta of 0.17, and R2 of 0.35 versus S&P 500 Index. Calculated based on daily prices since June 29, 2021.

• This portfolio participated in 30.37% of S&P 500 Index downside but only 27.58% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.17 may look defensive, but with R2 of 0.35 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R2 of 0.35 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.

Test has an expense ratio of 0.28%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Test ranks 12 for risk / return — in the bottom 12% of Portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

The current Test Sharpe ratio is 0.98 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.54 to 2.41, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of Test compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Test provided a 2.71% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Test. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Test was 9.48%, occurring on Oct 12, 2022. Recovery took 294 trading sessions.

The current Test drawdown is 3.74%.

The chart below shows the rolling one-month volatility.